查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
抗病毒药物的全球市场(2022年～2028年)
市场调查报告书
商品编码
1215701

抗病毒药物的全球市场(2022年～2028年)

Anti-Viral Drug Market 2022-2028
出版日期: | 出版商: Orion Market Research | 英文 | 商品交期: 2-3个工作天内

价格

全球抗病毒药物的市场规模，在预测期间内预计以4.0％的年复合成长率成长。

由于感染疾病的流行增加，需求和生产都以更广泛的等级剧增。还有製药公司的持续性研究开发与开发新药的投资，扩大市场成长的新可能性。再加上病毒感染疾病治疗药物的FDA核准高涨，也考虑为市场发展的突出方面之一 。

本报告提供全球抗病毒药物市场相关调查分析，市场概要，各市场区隔、地区的市场分析，竞争情形，企业简介等系统性资讯。

目录

第1章 报告概要

第2章 市场概要与洞察

  • 调查范围
  • 分析师的洞察和目前市场趋势
  • 波特分析

第3章 竞争情形

  • 主要企业分析
    • 概要
    • 财务分析
    • SWOT分析
    • 最近的开发
  • 主要策略分析

第4章 市场明细

  • 全球抗病毒药物市场:各类型
    • 非专利
    • 品牌
  • 全球抗病毒药物市场:各作用机制
    • 核甘酸聚合酵素抑制剂
    • 逆转录酵素抑制剂
    • 蛋白分解酵素抑制剂
    • 其他
  • 全球抗病毒药物市场:各用途
    • HIV
    • 肝炎
    • 疱疹病毒
    • 流感
    • 其他

第5章 地区分析

  • 北美
    • 美国
    • 加拿大
  • 欧洲
    • 英国
    • 德国
    • 义大利
    • 西班牙
    • 法国
    • 其他欧洲
  • 亚太地区
    • 中国
    • 印度
    • 日本
    • 韩国
    • 其他亚太地区
  • 其他地区
    • 南美
    • 中东、非洲

第6章 企业简介

  • AbbVie, Inc.
  • Abbott Laboratories
  • Arbutus Biopharma Corp.
  • Aurobindo Pharma, Ltd.
  • BioCryst Pharmaceuticals, Inc.
  • Bristol-Myers Squibb Co.
  • Candel Therapeutics, Inc.
  • Cipla, Inc.
  • Dr. Reddy's Laboratories, Ltd.
  • F. Hoffmann-La Roche AG
  • Gilead Sciences, Inc.
  • GlaxoSmithKline PLC
  • Johnson & Johnson Services, Inc.
  • Merck & Co., Inc.
  • Mylan N.V.
  • Pfizer, Inc.
  • Sanofi S.A.
  • Sino Biopharmaceutical, Ltd.
  • The Hep B Company
  • Zydus Lifesciences, Ltd.
Product Code: OMR2026757

Title:Global Anti-Viral Drug Market Size, Share, and Trends Analysis Report, by Type (Generic Anti-Viral Drugs and Branded Anti-Viral Drugs), by Mechanism of Action (Nucleotide Polymerase Inhibitor, Reverse Transcriptase Inhibitors, Protease Inhibitors, and Others), by Application (HIV, Hepatitis, Herpes Virus, Influenza, and Others), Forecast Period (2022-2028).

The global anti-viral drug market is anticipated to grow at a CAGR of 4.0% during the forecast period. The anti-viral drugs have found their effective use in the treatment of viral infections, such as hepatitis, HIV, influenza, and others. The increased prevalence of these infections has surged both the demand as well as production on a wider level. Continuous R&D and investment by pharma companies in new drug development are opening a new path for market growth. Rising FDA approvals of the drug for the treatment of viral infection are also considered one of the prominent aspects of market development. For instance, in March 2022, GlaxoSmithKline Plc and Vir Biotechnology, Inc got approval from the USFDA for the Emergency Use Authorization (EUA) Fact Sheet for sotrovimab, an investigational monoclonal antibody due to Omicron BA.2 Subvariant. Moreover, in November 2019, the USFDA approved a supplemental New Drug Application for Roche's Xofluza for the treatment of influenza in patients 12 years of age and older. Likewise, in March 2019, GlaxoSmithKline Plc received approval from the National Medical Products Administration for Viread (tenofovir disoproxil fumarate), an oral antiviral drug for chronic hepatitis B treatment.

The global anti-viral drug market is segmented based on type, mechanism of action, and application. Based on type, the market is sub-segmented into generic anti-viral drugs and branded anti-viral drugs. Based on the mechanism of action, the market is further classified into nucleotide polymerase inhibitors, reverse transcriptase inhibitors, protease inhibitors, and others. Similarly, based on application, it is classified into HIV, hepatitis, herpes virus, influenza, and others.

Geographically, the anti-viral drug market is segmented into North America, Europe, Asia-Pacific, and the Rest of the World. The Asia-Pacific region is anticipated to exhibit a high CAGR during the forthcoming period. Growth is attributable to the frequent outbursts of viral diseases, namely, swine flu, dengue, and Ebola in emerging economies. The increasing number of generic pharmaceutical companies present in this region would contribute to the growth. Moreover, the increasing incidence of viral infection and surging approval and expected commercialization of novel medicines for viral infections are the crucial factors anticipated to drive the North American anti-viral drug market growth during the forecast period.

The major market players in the global anti-viral drug market include AbbVie, Inc., Merck & Co., GlaxoSmithKline plc, Pfizer Inc., Mylan NV, Dr. Reddy's Laboratories Ltd., Apotex Inc., Teva Pharmaceutical Industries Ltd., Cipla Inc., Hikma Pharmaceuticals Ltd., Strides Pharma Science Ltd., Upsher-Smith Laboratories, among others. The market players are also contributing significantly to the growth of the market by the adoption of various strategies including mergers and acquisitions, geographical expansion, partnerships, collaborations, and new product launches, to stay competitive in the market.

Research Methodology

The market study of the global anti-viral drug is incorporated by extensive primary and secondary research conducted by the research team at OMR. Secondary research has been conducted to refine the available data to break down the market into various segments, and derive the total market size, market forecast, and growth rate. Different approaches have been worked on to derive the market value and market growth rate. Our team collects facts and data related to the market from different geography to provide a better regional outlook. In the report, the country-level analysis is provided by analyzing various regional players, regional tax laws and policies, consumer behavior, and macroeconomic factors. Numbers extracted from secondary research have been authenticated by conducting proper primary research. It includes tracking down key people from the industry and interviewing them to validate the data. This enables our analyst to derive the closest possible figures without any major deviations in the actual number. Our analysts try to contact as many executives, managers, key opinion leaders, and industry experts. Primary research brings authenticity to our reports.

Secondary Sources Include:

  • Financial reports of companies involved in the market.
  • Whitepapers, research papers, and news blogs.
  • Company websites and their product catalog.

The report provides an in-depth analysis of the market size and intended quality of the service preferred by consumers. The report will serve as a source for a 360-degree analysis of the market thoroughly integrating different models.

Market Segmentation

  • Global Anti-Viral Drug Research and Analysis by Type
  • Global Anti-Viral Drug Research and Analysis by Mechanism of Action
  • Global Anti-Viral Drug Research and Analysis by Application

The Report Covers:

  • Comprehensive research methodology of the global anti-viral drug market.
  • This report also includes a detailed and extensive market overview with key analyst insights.
  • An exhaustive analysis of macro and micro factors influencing the market guided by key recommendations.
  • Analysis of regional regulations and other government policies impacting the global anti-viral drug market.
  • Insights about market determinants that are stimulating the global anti-viral drug market.
  • Detailed and extensive market segments with the regional distribution of forecasted revenues.
  • Extensive profiles and recent developments of market players.

Table of Contents

1. Report Summary

  • Current Industry Analysis and Growth Potential Outlook
  • 1.1. Research Methods and Tools
  • 1.2. Market Breakdown
    • 1.2.1. By Segments
    • 1.2.2. By Region

2. Market Overview and Insights

  • 2.1. Scope of the Report
  • 2.2. Analyst Insight & Current Market Trends
    • 2.2.1. Key Findings
    • 2.2.2. Recommendations
    • 2.2.3. Conclusion
  • 2.3. Porter's Analysis

3. Competitive Landscape

  • 3.1. Key Company Analysis
    • 3.1.1. Overview
    • 3.1.2. Financial Analysis
    • 3.1.3. SWOT Analysis
    • 3.1.4. Recent Developments
  • 3.2. Key Strategy Analysis

4. Market Segmentation

  • 4.1. Global Anti-Viral Drug Market by Type
    • 4.1.1. Generic Anti-Viral Drugs
    • 4.1.2. Branded Anti-Viral Drugs
  • 4.2. Global Anti-Viral Drug Market by Mechanism of Action
    • 4.2.1. Nucleotide Polymerase Inhibitor
    • 4.2.2. Reverse Transcriptase Inhibitors
    • 4.2.3. Protease Inhibitors
    • 4.2.4. Others
  • 4.3. Global Anti-Viral Drug Market by Application
    • 4.3.1. HIV
    • 4.3.2. Hepatitis
    • 4.3.3. Herpes Virus
    • 4.3.4. Influenza
    • 4.3.5. Others

5. Regional Analysis

  • 5.1. North America
    • 5.1.1. United States
    • 5.1.2. Canada
  • 5.2. Europe
    • 5.2.1. UK
    • 5.2.2. Germany
    • 5.2.3. Italy
    • 5.2.4. Spain
    • 5.2.5. France
    • 5.2.6. Rest of Europe
  • 5.3. Asia-Pacific
    • 5.3.1. China
    • 5.3.2. India
    • 5.3.3. Japan
    • 5.3.4. South Korea
    • 5.3.5. Rest of Asia-Pacific
  • 5.4. Rest of the World
    • 5.4.1. Latin America
    • 5.4.2. Middle East & Africa

6. Company Profiles

  • 6.1. AbbVie, Inc.
  • 6.2. Abbott Laboratories
  • 6.3. Arbutus Biopharma Corp.
  • 6.4. Aurobindo Pharma, Ltd.
  • 6.5. BioCryst Pharmaceuticals, Inc.
  • 6.6. Bristol-Myers Squibb Co.
  • 6.7. Candel Therapeutics, Inc.
  • 6.8. Cipla, Inc.
  • 6.9. Dr. Reddy's Laboratories, Ltd.
  • 6.10. F. Hoffmann-La Roche AG
  • 6.11. Gilead Sciences, Inc.
  • 6.12. GlaxoSmithKline PLC
  • 6.13. Johnson & Johnson Services, Inc.
  • 6.14. Merck & Co., Inc.
  • 6.15. Mylan N.V.
  • 6.16. Pfizer, Inc.
  • 6.17. Sanofi S.A.
  • 6.18. Sino Biopharmaceutical, Ltd.
  • 6.19. The Hep B Company
  • 6.20. Zydus Lifesciences, Ltd.

LIST OF TABLES

  • 1. GLOBAL ANTI-VIRAL DRUG MARKET RESEARCH AND ANALYSIS BY TYPE, 2021-2028 ($ MILLION)
  • 2. GLOBAL GENERIC ANTI-VIRAL DRUGS MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
  • 3. GLOBAL BRANDED ANTI-VIRAL DRUGS MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
  • 4. GLOBAL ANTI-VIRAL DRUG MARKET RESEARCH AND ANALYSIS BY APPLICATION, 2021-2028 ($ MILLION)
  • 5. GLOBAL ANTI-VIRAL DRUG IN HIV MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
  • 6. GLOBAL ANTI-VIRAL DRUG IN HEPATITIS MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
  • 7. GLOBAL ANTI-VIRAL DRUG IN HERPES VIRUS MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
  • 8. GLOBAL ANTI-VIRAL DRUG IN INFLUENZA MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
  • 9. GLOBAL ANTI-VIRAL DRUG IN OTHER APPLICATIONS MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
  • 10. GLOBAL ANTI-VIRAL DRUG MARKET RESEARCH AND ANALYSIS BY MECHANISM OF ACTION, 2021-2028 ($ MILLION)
  • 11. GLOBAL NUCLEOTIDE POLYMERASE INHIBITOR MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
  • 12. GLOBAL REVERSE TRANSCRIPTASE INHIBITORS MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
  • 13. GLOBAL PROTEASE INHIBITORS MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
  • 14. GLOBAL OTHER MECHANISM OF ACTION MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
  • 15. GLOBAL ANTI-VIRAL DRUG IN INFLUENZA MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
  • 16. GLOBAL ANTI-VIRAL DRUG MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
  • 17. NORTH AMERICAN ANTI-VIRAL DRUG MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2021-2028 ($ MILLION)
  • 18. NORTH AMERICAN ANTI-VIRAL DRUG MARKET RESEARCH AND ANALYSIS BY TYPE, 2021-2028 ($ MILLION)
  • 19. NORTH AMERICAN ANTI-VIRAL DRUG MARKET RESEARCH AND ANALYSIS BY MECHANISM OF ACTION, 2021-2028 ($ MILLION)
  • 20. NORTH AMERICAN ANTI-VIRAL DRUG MARKET RESEARCH AND ANALYSIS BY APPLICATION, 2021-2028 ($ MILLION)
  • 21. EUROPEAN ANTI-VIRAL DRUG MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2021-2028 ($ MILLION)
  • 22. EUROPEAN ANTI-VIRAL DRUG MARKET RESEARCH AND ANALYSIS BY TYPE, 2021-2028 ($ MILLION)
  • 23. EUROPEAN ANTI-VIRAL DRUG MARKET RESEARCH AND ANALYSIS BY MECHANISM OF ACTION, 2021-2028 ($ MILLION)
  • 24. EUROPEAN ANTI-VIRAL DRUG MARKET RESEARCH AND ANALYSIS BY APPLICATION, 2021-2028 ($ MILLION)
  • 25. ASIA-PACIFIC ANTI-VIRAL DRUG MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2021-2028 ($ MILLION)
  • 26. ASIA-PACIFIC ANTI-VIRAL DRUG MARKET RESEARCH AND ANALYSIS BY TYPE, 2021-2028 ($ MILLION)
  • 27. ASIA-PACIFIC ANTI-VIRAL DRUG MARKET RESEARCH AND ANALYSIS BY MECHANISM OF ACTION, 2021-2028 ($ MILLION)
  • 28. ASIA-PACIFIC ANTI-VIRAL DRUG MARKET RESEARCH AND ANALYSIS BY APPLICATION, 2021-2028 ($ MILLION)
  • 29. REST OF THE WORLD ANTI-VIRAL DRUG MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2021-2028 ($ MILLION)
  • 30. REST OF THE WORLD ANTI-VIRAL DRUG MARKET RESEARCH AND ANALYSIS BY TYPE, 2021-2028 ($ MILLION)
  • 31. REST OF THE WORLD ANTI-VIRAL DRUG MARKET RESEARCH AND ANALYSIS BY MECHANISM OF ACTION, 2021-2028 ($ MILLION)
  • 32. REST OF THE WORLD ANTI-VIRAL DRUG MARKET RESEARCH AND ANALYSIS BY APPLICATION, 2021-2028 ($ MILLION)

LIST OF FIGURES

  • 1. GLOBAL ANTI-VIRAL DRUG MARKET SHARE BY TYPE, 2021 VS 2028 (%)
  • 2. GLOBAL ANTI-VIRAL DRUG MARKET SHARE BY MECHANISM OF ACTION, 2021 VS 2028 (%)
  • 3. GLOBAL ANTI-VIRAL DRUG MARKET SHARE BY APPLICATION, 2021 VS 2028 (%)
  • 4. GLOBAL ANTI-VIRAL DRUG MARKET SHARE BY REGION, 2021 VS 2028 (%)
  • 5. GLOBAL GENERIC ANTI-VIRAL DRUGS MARKET SHARE BY REGION, 2021 VS 2028 (%)
  • 6. GLOBAL BRANDED ANTI-VIRAL DRUGS MARKET SHARE BY REGION, 2021 VS 2028 (%)
  • 7. GLOBAL ANTI-VIRAL DRUG IN HIV MARKET SHARE BY REGION, 2021 VS 2028 (%)
  • 8. GLOBAL ANTI-VIRAL DRUG IN HEPATITIS MARKET SHARE BY REGION, 2021 VS 2028 (%)
  • 9. GLOBAL ANTI-VIRAL DRUG IN HERPES VIRUS MARKET SHARE BY REGION, 2021 VS 2028 (%)
  • 10. GLOBAL ANTI-VIRAL DRUG IN INFLUENZA MARKET SHARE BY REGION, 2021 VS 2028 (%)
  • 11. GLOBAL ANTI-VIRAL DRUG IN OTHER APPLICATIONS MARKET SHARE BY REGION, 2021 VS 2028 (%)
  • 12. GLOBAL NUCLEOTIDE POLYMERASE INHIBITOR MARKET SHARE BY REGION, 2021 VS 2028 (%)
  • 13. GLOBAL REVERSE TRANSCRIPTASE INHIBITORS MARKET SHARE BY REGION, 2021 VS 2028 (%)
  • 14. GLOBAL PROTEASE INHIBITORS MARKET SHARE BY REGION, 2021 VS 2028 (%)
  • 15. GLOBAL OTHER MECHANISM OF ACTION MARKET SHARE BY REGION, 2021 VS 2028 (%)
  • 16. GLOBAL ANTI-VIRAL DRUG IN INFLUENZA MARKET SHARE BY REGION, 2021 VS 2028 (%)
  • 17. US ANTI-VIRAL DRUG MARKET SIZE, 2021-2028 ($ MILLION)
  • 18. CANADA ANTI-VIRAL DRUG MARKET SIZE, 2021-2028 ($ MILLION)
  • 19. UK ANTI-VIRAL DRUG MARKET SIZE, 2021-2028 ($ MILLION)
  • 20. FRANCE ANTI-VIRAL DRUG MARKET SIZE, 2021-2028 ($ MILLION)
  • 21. GERMANY ANTI-VIRAL DRUG MARKET SIZE, 2021-2028 ($ MILLION)
  • 22. ITALY ANTI-VIRAL DRUG MARKET SIZE, 2021-2028 ($ MILLION)
  • 23. SPAIN ANTI-VIRAL DRUG MARKET SIZE, 2021-2028 ($ MILLION)
  • 24. REST OF EUROPE ANTI-VIRAL DRUG MARKET SIZE, 2021-2028 ($ MILLION)
  • 25. INDIA ANTI-VIRAL DRUG MARKET SIZE, 2021-2028 ($ MILLION)
  • 26. CHINA ANTI-VIRAL DRUG MARKET SIZE, 2021-2028 ($ MILLION)
  • 27. JAPAN ANTI-VIRAL DRUG MARKET SIZE, 2021-2028 ($ MILLION)
  • 28. SOUTH KOREA ANTI-VIRAL DRUG MARKET SIZE, 2021-2028 ($ MILLION)
  • 29. REST OF ASIA-PACIFIC ANTI-VIRAL DRUG MARKET SIZE, 2021-2028 ($ MILLION)
  • 30. REST OF THE WORLD ANTI-VIRAL DRUG MARKET SIZE, 2021-2028 ($ MILLION)